Explore XRAY stock analysis with latest price, earnings, technicals, and valuation. Is XRAY stock a buy? Get analyst ratings, forecast, and risks for Dentsply Sirona investors.
Introduction
Dentsply Sirona makes dental products like implants, tools, and equipment for dentists worldwide. XRAY stock draws attention amid healthcare sector shifts and restructuring news. Broader market conditions, including rising healthcare costs, impact medtech stocks like XRAY.
Investors watch XRAY stock price for signs of recovery after losses. Recent Q4 earnings and cost cuts fuel debate on its future.
Latest Stock Price & Trend
XRAY stock closed at $14.33 on February 27, 2026, after a volatile session with day’s range of $14.13-$14.35. It fell slightly from prior days but gained nearly 8% pre-market on restructuring news.
Over five days, XRAY stock shows mixed moves amid earnings release. One-month trend dips about 13%, reflecting year-end pressures. Three-month performance stays sideways near $14 levels.
Six-month trend rises 1.2%, lagging industry growth of 24%. Year-to-date, XRAY stock drops sharply, down over 30% from yearly highs.
The 52-week range spans $9.85 low to $27.48 high, with current price near the bottom third. Overall trend looks bearish short-term but hints at stabilization, signaling caution for investors until momentum builds.
Technical Analysis
Support levels sit around $12.16 (52-week low) and $14, where buyers stepped in recently. Resistance looms at $19-$20, matching analyst targets.
RSI reads 61, neutral—not overbought (above 70) or oversold (below 30). This gauge measures speed of price changes, helping spot reversal risks.
MACD shows bearish momentum with line below signal, suggesting sellers dominate short-term. It tracks trend strength via moving average differences.
The 50-day moving average hovers above current price, while 200-day is supportive below. No golden cross (50-day over 200-day bullish) or death cross yet.
Volume trended up on earnings day at 2.4 million shares, above average, indicating interest. Higher volume confirms trends for beginners.
This chart shows XRAY stock’s recent price action with key levels marked.
Analyst Ratings & Price Targets
Of 12-14 analysts, ratings split: 2 buys, 11 holds, 1 sell—consensus “Hold”. Average price target is $18-$19.10, implying 25-33% upside from $14.33.
Highest target $24, lowest $14; recent holds from firms like those lowering to $11 but maintaining neutral. No major upgrades post-earnings.
Analyst sentiment points to fair value but limited enthusiasm, guiding investors to wait for catalysts.
Insider Activity
Insiders bought $611k last year by two traders, outpacing $261k sells by one. Recent purchases include CEO Simon Campion (11,306 shares Nov 2024) and director Gregory Lucier (multiple buys totaling 15k+ shares in late 2024).
Over 10 years, buys total $15M vs $8M sells, showing net confidence. No large recent sells signal caution.
This buying trend implies management optimism amid challenges.
Valuation Analysis
Trailing P/E is negative at -2.97 due to losses (EPS -$4.76 TTM). Forward P/E 7.39 looks cheap.
Price-to-sales around 0.8 based on $3.67B TTM revenue. Revenue fell 3-4% YoY to $3.68B; EPS down but adjusted $1.60 full-year.
Free cash flow strong at $160M Q4; cash $326M, debt $2.42B (net debt/EBITDA 3.0). Vs peers like Align (ALC), XRAY trades lower multiples but higher debt.
XRAY stock appears undervalued on forward metrics, but risks from losses keep it cautious.
Recent Earnings & Catalysts
Q4 2025 revenue hit $961M, up 6.2% YoY (2.5% constant currency), beating estimates. Adjusted EPS 27 cents missed slightly but up 3.8%; GAAP loss 74 cents.
Full-year revenue $3.68B down 3%, adjusted EPS $1.60 down 4.6%. Guidance soft for 2026; new $120M restructuring, dividend halt for debt paydown and buybacks.
Catalysts: 24-month growth plan, innovation in dental tech. Earnings drove pre-market pop despite miss.
Bullish Case
Steady revenue segments and 6% Q4 growth show momentum. Restructuring frees $120M for efficiency.
Dental market demand rises with aging populations. Tech edges in implants position well.
Capital shift to buybacks boosts shareholder value long-term.
Bearish Case
Revenue down 3-4% YoY signals slowing growth. Losses persist, margins pressured.
Competition from Align, Straumann erodes share. High debt at 180% equity ratio worries.
Regulatory hurdles in medtech add risks.
Market Sentiment
Short interest data limited, but institutional ownership high at 95.7%. Inflows $1.26B vs outflows $659M last year—net positive.
Options activity not detailed; retail focuses on turnaround. Institutions like Vanguard hold big stakes.
Sentiment neutral, leaning optimistic on restructuring.
Short-Term Outlook
Technicals show bearish MACD, neutral RSI. Volume spikes on news suggest volatility next weeks.
Momentum from restructuring may lift XRAY stock price if markets stay steady. Watch $14 support.
Medium to Long-Term Outlook
Strong dental market aids business model. Competitive position fair with innovation focus.
Financial health improves via debt cuts; hold for long-term investors watching growth plan. Accumulate on dips if execution succeeds.
FAQ
Is XRAY stock a buy right now? Hold per analysts; undervalued forward but risks high.
What is the price target for XRAY stock? Average $18-19, up 25-33%.
What are major risks for XRAY stock? Losses, debt, competition.
XRAY earnings outlook? Soft 2026 guidance post-Q4 beat on revenue.
XRAY long term outlook? Potential recovery via restructuring.
Suggestions
Compare with Opendoor stock analysis
See our Straumann Holdings stock forecast
Read our dental medtech sector valuation
Final Balanced Conclusion
Hold XRAY stock. Restructuring offers upside, but ongoing losses and debt warrant caution—watch execution.
Disclaimer: This article is for informational purposes only and not financial advice.